Silence Therapeutics
SLN
2 hedge funds and large institutions have $8.13M invested in Silence Therapeutics in 2020 Q3 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.65% more ownership
Funds ownership: 0% → 0.65% (+0.65%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
+$9.98M |
| 2 |
Morgan Stanley
New York
|
+$37K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LOAMU
1
Lombard Odier Asset Management (USA)
New York
| $8.1M | +$9.98M | +540,000 | New |
|
|
2
Morgan Stanley
New York
| $32K | +$37K | +2,000 | New |
|
SLN Hedge Fund Activity: Q3 2020 in Review
2 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q3 2020, worth a combined $8.13M.
Buyers outnumbered sellers: 2 funds opened new SLN positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Lombard Odier Asset Management (USA), opening a new position worth an estimated $9.98M.
- 2 institutional investors held Silence Therapeutics (SLN) as of Q3 2020, up from 0 in Q2 2020.
- Funds reported $8.13M of Silence Therapeutics stock for Q3 2020.
- 2 funds opened new Silence Therapeutics positions in Q3 2020 and 0 closed out, a net change of +2 holders.
- The largest Silence Therapeutics buyer in Q3 2020 was Lombard Odier Asset Management (USA), an estimated $9.98M added.
Based on aggregated 13F filings for Q3 2020.